Dhuwit awis saben siji saham Akero Corp (AKRO)

The cash per share forecast displayed on the main Akero Therapeutics (AKRO) chart on GURU.Markets shows an indicator value of 8.97. Volatility is driven by the threat of failed trials for the lead drug and a potential collapse in value. The situation is further complicated by a critical dependence on a single product; however, the existence of several research programs in liver metabolism partially mitigates the risks of total failure.
Rincian analitis perusahaan Akero Therapeutics

For Akero Therapeutics (AKRO), the cash per share chart reflects financial stability during the period leading up to the commercialization of efruxifermin. This metric is calculated as the difference between total cash assets and all liabilities, divided by the number of shares, allowing investors to assess the net liquidity reserve per share available to cover operating expenses and future expansion.